- Goal to develop Claudin 18.2 스피드 바카라 사이트 therapy for solid tumors with Seoul National University
- Development of 'AT501,' a HER2-targeted switchable 스피드 바카라 사이트 treatment candidate
[by Ji, Yong Jun] AbClon announced on April 14 that it has successfully secured preclinical technology for a chimeric antigen receptor (CAR-T) treatment targeting solid tumors, following its previous development efforts for 'hematologic malignancies.’
스피드 바카라 사이트 is currently conducting Phase 2 clinical trials in Korea for its first CAR-T treatment candidate, 'AT101,' targeting hematologic malignancies. The company recently completed a technology transfer agreement with a partner in Turkey, and its strategy is to expand indications for solid tumors, leveraging the clinical progress and performance of AT101 in blood cancer treatment.
스피드 바카라 사이트 is co-developing a CAR-T treatment targeting 'Claudin18.2' in partnership with the research team led by Professor Chung Jun-ho of Seoul National University College of Medicine. Claudin18.2 is a membrane protein highly expressed in treatment-resistant solid tumors, including gastric and pancreatic cancers. Given the limited efficacy and high resistance associated with current treatment options, this target represents a critical area of unmet medical needs.
Professor Chung’s research team developed a Claudin 18.2-specific antibody using VHH (single domain antibody) and scFv (single chain variable fragment) technologies, derived through specialized animal immunization and antibody gene engineering. 스피드 바카라 사이트 stated that, by incorporating this antibody, it has demonstrated the preclinical potential of CAR-T cell therapy for the treatment of solid tumors.
The company is also developing 'AT501,' a next-generation switchable 스피드 바카라 사이트 treatment candidate targeting 'human epidermal growth factor receptor type 2 (HER2).' AT501 is based on a platform technology that allows precise control over 스피드 바카라 사이트 cell activation through the administration of a specific switch protein. This switch technology enables selective targeting of HER2 and has demonstrated potent antitumor effects in animal models. The company further noted that this approach offers the benefit of enhancing anticancer effects in treatment-responsive or relapsed models through repeated administration of the switch protein.
In addition, 스피드 바카라 사이트 is developing a CAR-T treatment targeting 'CD30' for the treatment of relapsed or refractory lymphoma. This project is being carried out in collaboration with Dr. Marco Ruella’s research team at the Perelman School of Medicine, University of Pennsylvania (UPENN), in the United States. The company anticipates that this therapy could offer a new treatment option for patients who do not respond to existing treatments. In particular, the candidate is being designed as a next-generation CAR-T therapy that aims to overcome the challenges of the tumor microenvironment (TME) through the application of BTLA (B and T lymphocyte attenuator) gene-editing technology.
"We plan to continuously broaden the range of indications for refractory solid tumors by integrating our antibody platform technology with our cell therapy development capabilities," an 스피드 바카라 사이트 official said. "We will pursue a differentiated strategy in novel drug development in the global oncology market and establish ourselves as a leading company in the next-generation immuno-oncology industry."